Navigation Links
Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference

Interim Phase 1 Data Confirms Safety and Tolerability

PLYMOUTH MEETING, Pa., Aug. 8 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced interim data from the first Phase 1 clinical study of trodusquemine (MSI-1436) for the treatment of obesity. Anthony DelConte, M.D., Vice President, Clinical Research and Development, presented "Trodusquemine: A Novel Aminosterol for the Treatment of Obesity and Related Metabolic Disorders," during the IBC 12th Annual World Congress on Drug Discovery & Development of Innovative Therapeutics, August 6-8 in Boston.

The presentation summarized the clinical trial design of the single ascending dose Phase 1 study of MSI-1436 to evaluate safety and pharmacokinetics of the drug in healthy obese volunteers. Dr. DelConte provided interim data from the initial cohorts in the double-blind, randomized, placebo-controlled trial which included safety and pharmacokinetic (PK) data from 20 treated subjects and eight vehicle controls in four sequential dose groups. According to Dr. DelConte, PK profiles from the study thus far show a predictable pattern with minimal subject-to-subject variability and linearity across the range of doses studied. To date, no serious adverse events have been reported. It was emphasized that further study is needed to establish dose limiting toxicity and proof-of-concept in humans.

"These initial findings validate the preclinical safety and PK work done by Genaera scientists. We are encouraged by these findings and will continue to further characterize the safety profile and provide proof of concept for trodusquemine in obesity and type 2 diabetes management," commented Jack Armstrong, President and CEO. "We anticipate a steady flow of clinical information in the second half of 2007 as our clinical studies progress to broader populations."

About Trodusquemine (MSI-1436)

Trodusquemine (MSI-1436) is the first drug candidate that acts both centrally and peripherally to selectively inhibit the established and validated enzyme target, protein tyrosine phosphatase 1B (PTP-1B). The dual locations of MSI-1436 action make the drug a promising candidate for both obesity and type 2 diabetes. By inhibiting PTP-1B, trodusquemine is expected to decrease appetite and normalize blood sugar as PTB-1B is central to both the insulin and leptin pathways. Based on this unique mechanism of action, trodusquemine has the potential to bridge the treatment for two of the most serious metabolic diseases, obesity and type 2 diabetes. In addition, trodusquemine has overcome selectivity concerns that other compounds that target PTP-1B have failed to overcome. Preclinical studies demonstrate that trodusquemine is a potent, highly-selective and reversible inhibitor of PTP-1B. In vitro kinetics demonstrate that trodusquemine is an allosteric, noncompetitive inhibitor of PTP-1B, binding to a site different from the catalytic site of PTP-1B. Data also demonstrate that trodusquemine can produce consistent, sustainable weight loss in a variety of animal models and appears to overcome metabolic readjustment, which often limits sustained weight loss during caloric restriction. Trodusquemine suppresses appetite, causes differential weight loss, reduces adipocyte size, reduces body fat (with no reduction of lean mass), and improves glucose tolerance via inhibition of a unique combination of signaling pathways in a mouse model of diet induced obesity (DIO).

About Genaera

Genaera Corporation is focused on advancing the science and treatment of metabolic diseases. The Company has significant market opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes and is presently in a Phase 1 trial in obesity. In addition, Genaera has a value-driven, fully out-licensed partnership with MedImmune, Inc. for a second core program that is presently undergoing Phase 2 clinical testing in asthma. Genaera is committed to directing resources to its core program and the aggressive clinical development of its key assets to build stockholder value.

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. Such statements include, among others, statements regarding these preliminary results, clinical development plans and prospects for Genaera's programs including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM), or squalamine. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to: Genaera's history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the risk that clinical trials for Genaera's product candidates, including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM), or squalamine may be delayed or may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera's reliance on its collaborators, in connection with the development and commercialization of Genaera's product candidates; market acceptance of Genaera's products, if regulatory approval is achieved; competition; general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industry; and the other risks and uncertainties discussed in this announcement and in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.

Genaera Corporation Susan Neath - Porter Novelli Life Sciences

Investor Relations Media

(610) 941-5675 (609) 529-0676

SOURCE Genaera Corporation

Copyright©2007 PR Newswire.

Related medicine technology :

1. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
2. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
3. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
4. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
5. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
6. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
7. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
(Date:10/12/2015)... October 12, 2015 ... to grow at 7.2% CAGR, microscopy market ... rising focus on nanotechnology, technological advancements, and ... report available with ... . --> Complete report on ...
(Date:10/12/2015)...   Royal Philips (NYSE: PHG, AEX: PHIA), ... a collaboration with Genomic Health , Inc. (NASDAQ: ... diagnostic tests, to leverage Philips digital pathology tools in ... testing processes.    --> ... samples and plays a crucial role in the diagnosis ...
(Date:10/12/2015)... , Oct. 12, 2015 Indivior PLC (LON: ... District of Delaware granted the Company,s ... Pharmaceuticals, Abbreviated New Drug Application (ANDA) No. 205299 to market ... (buprenorphine and naloxone) Sublingual Film (CIII) in the ... --> Since August 2013, Indivior has received Paragraph IV ...
Breaking Medicine Technology:
(Date:10/12/2015)... ... 2015 , ... The American Society of Clinical Hypnosis (ASCH) ... and clinical training in a health care discipline. , Many practitioners claim ... losing weight, managing pain, or stopping smoking, etc. Frequently, extravagant statements and guarantees ...
(Date:10/12/2015)... ... October 12, 2015 , ... AcousticSheep LLC, creators of ... in honor of Breast Cancer Awareness Month. During the month of October, ... a SleepPhones® Classic product to a breast cancer patient at the Cleveland Clinic. ...
(Date:10/12/2015)... ... October 12, 2015 , ... To help ... its charitable donation to the National Breast Cancer Foundation. The National Breast Cancer ... breast cancer through early detection, education, and support services. , The annual campaign ...
(Date:10/12/2015)... ... October 12, 2015 , ... NFL football fans who are interested in having an opportunity to ... CLICK HERE to donate to Smile for a Lifetime (S4L) Foundation and gift ... all-inclusive trip to the 2016 NFL Super Bowl! , Donors contributing $20.00 or more between ...
(Date:10/12/2015)... , ... October 12, 2015 , ... The translation for ... seamless migration of complete ARIS installations into the Microsoft world. The ARIS models ... As Microsoft Visio® is very familiar for both IT and Office users it is ...
Breaking Medicine News(10 mins):